CureVac to withdraw first-generation COVID-19 vaccine candidate By Reuters
[ad_1]
© Reuters. FILE PHOTO: A volunteer receives a dose of CureVac vaccine or a placebo throughout a research by the German biotech agency CureVac as a part of a testing for a brand new vaccine towards the coronavirus illness (COVID-19), in Brussels, Belgium March 2, 2021. REUTERS/Yves HBERLIN (Reuters) – CureVac will withdraw its first-generation COVID-19 vaccine candidate and deal with collaborating with GSK to develop second-generation mRNA vaccine expertise as an alternative, the Germany-based biotechnology firm stated on Tuesday.
The corporate stated it would withdraw its first-generation vaccine candidate CVnCoV, which failed late-stage trials with 47% accuracy in June, as a result of a possible overlap with approval timelines for a second-generation candidate.
The earliest potential approval of CVnCoV would have come within the second quarter of 2022 when the candidates from the second-generation vaccine program are anticipated to progress to late-stage medical growth by that point, CureVac stated.
Fusion Media or anybody concerned with Fusion Media won’t settle for any legal responsibility for loss or harm on account of reliance on the data together with information, quotes, charts and purchase/promote indicators contained inside this web site. Please be totally knowledgeable relating to the dangers and prices related to buying and selling the monetary markets, it is among the riskiest funding varieties potential.
[ad_2]
